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ABSTRACT 
 
Objective: Restricted pulmonary function is found among people with diabetes. This study aimed to 
investigate the dose-response relationship between pulmonary function measurements (forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC)) and risk of metabolic 
syndrome (MS) /type 2 diabetes. 
 
Methods: 1,454 adults in rural Victoria, Australia and 5,824 adults in Nanjing, China from randomly 
selected households provided clinical history, oral glucose tolerance test, lipids, anthropometric, blood 
pressure and spirometric measurements. MS was defined by International Diabetes Federation criteria.  
Adjusted odds ratios for MS and type 2 diabetes with lung capacity measurements were estimated 
using logistic regression. Dose-response relationships were explored using restricted cubic spline 
models. 
 
Results: There was a non-linear relationship between FEV1 and the risk of type 2 diabetes and MS 
(both P<0.0001) both in Australian and Chinese populations. The FEV1 associated with the lowest 
risk of type 2 diabetes and MS was above 2.70L (95%CI: 2.68 to 2.72L and 2.65 to 2.76L in Chinese 
and Australian populations respectively). The discrimination of the model could be significantly 
improved using the FEV1 threshold both in the Australian and Chinese populations. 
 
Conclusions: In both Australian and Chinese populations, the risk of type 2 diabetes and MS is lowest 
with a FEV1 of 2.65-2.76 L. This might be used in clinical practice in different countries as a prompt 
to screen for type 2 diabetes and MS in patients with obstructive lung disease and to ensure there was 
no abnormal glucose metabolism before the commencement of steroids if indicated. 
 
INTRODUCTION 
Type 2 diabetes imposes significant health and economic burdens on both developed and developing 
countries 
2
 and its prevalence is increasing
1
.  Although this increase may be due to increased obesity, 
other potential risk factors have been proposed such as impaired pulmonary function 
3
. 
Epidemiological and clinical studies suggest that adults with diabetes have lower forced vital capacity 
(FVC) and forced expiratory volume in one second (FEV1) compared with their non-diabetic 
counterparts 
4,5
. Furthermore, the lung function of patients with diabetes is inversely related to blood 
glucose level, duration of diabetes and the severity of diabetes, independent of smoking or obesity 
6,7
.  
 
However the association between lung capacity and type 2 diabetes is not consistent.  This might be 
due to different research design, ethnic variation or different analytical methods. The association 
between lung capacity and metabolic syndrome (MS) has also not been investigated.   We therefore 
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undertook a joint analysis between Chinese and Australian populations to assess the dose response 
relationship between lung capacity measures (FEV1 and FVC) for MS and type 2 diabetes. 
 
METHODS 
The Crossroads study was carried out between June 2001 and March 2003 among residents of the 
seven main towns in the Goulburn Valley, Victoria, Australia (populations 2094–35,828), as 
previously described 
8,9,10
.  
 
The Nanjing Community Cardiovascular Risk Survey was carried out, using random cluster 
sampling
11
, between 2011and 2013 among the residents of 6 communities in Nanjing, Jiangsu 
Province, China (population 0.7 million-1.3 million). In each community, one street district or 
township was randomly selected. All households (n=6,445) in the selected street or town were 
included with only one participant aged ≥ 20 years selected from each household, without 
replacement. Overall, 5,824 residents completed the survey and examination (response rate of 90%).  
 
In both studies, questionnaires were completed, wherever possible, through face-to-face interviews by 
trained research staff. Questions included age, sex, education, cigarette smoking, a self-reported 
history of asthma, chronic obstructive pulmonary disease (COPD), and known diabetes. 
 
In both studies, blood pressure and body measurements were taken three times using a standardized 
methodology and the mean of the two closest recordings was used.  Overweight/obesity were defined 
as 25.0–29.9/≥30.0 kg/m2 respectively9.  
 
Measurements of FEV1 and FVC were obtained using spirometry (Vitalograph, Buckingham, UK). 
Each participant completed two spirometry attempts while seated. Where the two readings differed 
significantly, a third measurement was taken 
10
. 
 
Fasting blood specimens were processed at the examination center
12
. Plasma glucose and lipid levels 
were measured by automated analyser (Australian: Hitachi 917R autoanalyser (Hitachi, Tokyo, 
Japan); Nanjing: Olympus AU600 autoanalyser (Olympus Optical, Tokyo, Japan)).Type 2 diabetes 
was defined using WHO criteria 
8
 or by self-report if previously diagnosed, and MS using 
International Diabetes Federation (IDF) criteria 
13
. Hypertension was considered present if reported as 
having been diagnosed by a doctor or nurse 
14,15
. Patients with Type 2 diabetes overlapping within the 
MS definition were only defined as having ‘Type 2 diabetes’ in the analysis. 
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Statistics 
Continuous variables were compared using the Kruskal–Wallis test and categorical variables using the 
chi-squared test.  Multiple linear regression was used to investigate the association between lung 
capacity measures (FEV1 and FVC) and linear variables including glucose, lipid profiles.  The 
relationship between lung capacity measurements and the odds ratios of MS and diabetes were 
estimated using a linear model (unconditional Logistic Model), a natural cubic spline model with four 
equally spaced knots determined from the levels of lung capacity measurements, and a quadratic 
spline model
16,17
. The natural cubic spline model was chosen as the best fit model for the relationship 
curve by its minimum Akaike information criterion (AIC) compared with the linear model or 
quadratic spline model 
18
. 
 
The break-point test was carried out to target the potential thresholds (the 5
th
 percentile (P5) to the 95
th
 
percentile (P95) of lung capacity measures) by incorporating the piecewise term into the cubic spline 
model 
19
. The threshold with a significant break in the regression coefficients and achieving the 
minimum AIC was chosen as the final threshold
20
. The 95% CI of the threshold was obtained from 
1000 bootstrap samples 
21
.  
 
For sensitivity analysis, the natural cubic spline models for the overall dataset were repeated using 
other potential knots, chosen to lie within the range for minimum to maximum measure of lung 
capacity
20
. Modelling in the data rich range (in the 5
th
 percentile to the 95
th
 percentile of measure of 
lung capacity) was processed as another sensitivity analysis
20
. The linear test was used in the natural 
cubic spline model to test the linearity of the relationship
22,23
. 
 
All analyses were two-tailed, performed using STATA (STATA/SE 13.0 Stata Corp., College Station, 
TX, USA) with P value < 0.05 were considered statistically significant. 
Ethics, consent and permissions 
The Goulburn Valley Health Ethics Committee approved the  Crossroads study (approval number 
GVH – 3/99). The Institutional Review Board of Jiangsu Province Hospital on Integration of Chinese 
and Western Medicine approved the Nanjing study (approval number 11-006).  Signed, informed 
consent was obtained from all participants.   
 
RESULTS AND DISCUSSION 
Results  
MS/type 2 diabetes were present in 28.9%/9.4% in Crossroads and 24.1%/8.1% in Nanjing.  In both 
populations, mean ages and gender proportions were similar overall (Table 1) and participants with 
MS/type 2 diabetes were more likely to be older and male.  
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Both Chinese and Australian participants with MS or type 2 diabetes were more likely to have lower 
lung capacity measurements.   Figure 1 shows that the median (interquartile range) of FEV1 was 2.42 
(2.07, 2.89)L, 2.12 (1.81, 2.43)L, and 2.15 (1.81, 2.52)L among Chinese participants and  2.95 (2.44, 
3.49)L, 2.73 (2.12, 3.38)L, and 2.35 (1.92, 2.94)L among Australian participants  without MS/ type 2 
diabetes, with MS and with type 2 diabetes, respectively. 
 
Figure 1 also shows that the median (interquartile range) of FEV1 was 2.99 (2.50, 3.56)L, 2.55 (2.16, 
3.00)L, and 2.60 (2.18, 3.15)L among Chinese participants and  3.67 (3.06, 4.42)L, 3.45 (2.69, 4.17)L, 
and 2.99 (2.42, 3.63)L among Australian participants  without MS/ type 2 diabetes, with MS and with 
type 2 diabetes, respectively. 
 
The relationships between clinical measurements and lung capacity measurements (both FEV1 and 
FVC) are shown  in e-Figures 1 and 2. Significant reverse associations were identified between lung 
capacity measurements (both FEV1 and FVC) and both fasting glucose and lipids in the Chinese and 
Australian general populations.  (Tables 2 and 3).  
 
Dose-response relationship between lung capacity measurements and type 2 diabetes/Metabolic 
syndrome 
There was a non-linear relationship (Linear test: both P<0.0001) between FEV1 and adjusted odds 
ratios for both type 2 diabetes and MS, with clear evidence of a threshold estimated at 1.76L (95%CI: 
1.74 to 1.78L and 1.73 to 1.79L in both the Chinese and Australian populations respectively) (Figures 
2 and 3) and 2.70 (95%CI: 2.68 to 2.72)L only in the Chinese population by threshold models. Similar 
non-linear relationships (Linear test: both P<0.0001) were observed between FVC and adjusted odds 
ratios for type 2 diabetes and a threshold was identified at 2.00L (95%CI: 1.82 to 2.21L and 1.61 to 
2.42L in Chinese and Australian populations respectively) (Figure 2). 
A non-linear association (Linear test: both P<0.0001) between FEV1 and adjusted odds ratio of both 
type 2 diabetes and MS with a threshold 2.70L (95%CI: 2.68 to 2.72L and 2.65 to 2.76L in Chinese 
and Australian populations respectively) were also found in sensitivity analysis modelling the 
association within the data rich range (1.5 to 3.5L for FEV1; e-Figures 3 and 4). Below the threshold, 
the adjusted odds ratio decreased with the increase of FEV1. Above the threshold, the adjusted odds 
ratio remained unchanged.  A similar analysis for FVC was not significant, as the adjusted odds ratio 
decreased linearly with the increase in FVC in both populations.  
 
The adjusted odds ratios of MS decreased between an FEV1 of 1.76 and 2.70L in both populations 
although neither increased nor decreased risk was  observed below 1.76L. The adjusted odds ratio did 
not decrease above 2.70L of FEV1 in the Chinese but not Australian population. A linear association 
between FVC and adjusted odds ratio of MS was found in both populations. 
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Discussion 
This joint study was undertaken to relate pulmonary function measurements to the risk of MS/type 2 
diabetes in both Chinese and Australian populations in the light of the growing evidence of the 
existence of their mutual association. We focused our investigation on the shape of the relationship, 
assessing the evidence for non-linearity and, in particular, on the existence of a threshold. In our 
analyses, we found consistent evidence that the associations are non-linear between FEV1 and 
metabolic disorders (both type 2 diabetes and MS). Threshold analysis demonstrated two FEV1 
thresholds for type 2 diabetes and MS in both the Chinese and Australian populations: 1.76 L and 
2.70L of FEV1. The risk of type 2 diabetes and MS decreased in the 1.76 to 2.70 range of FEV1 but 
neither  increased nor decreased risk was observed below 1.76L or above 2.70L. 
 
Both FEV1 and FVC as lung capacity measurements have been identified as possible predictors for 
the development of type 2 diabetes in cross-sectional studies and cohort studies
24–26
. It has been 
widely accepted that low lung function is associated with the subsequent occurrence of diabetes and 
related conditions
6,27
. For example, in the Normative aging study
25
, it was found that a lower FEV1 
and lower FVC at baseline predicted hyperinsulinemia and estimated insulin resistance over 20 years 
of follow-up, independent of age, adiposity, and smoking. It was also found in a Swedish study that 
4,637 non diabetic middle-aged men, baseline mean vital capacity was 10% lower among 116 men 
who developed diabetes during 6-years follow-up than those who did not develop diabetes
28
. 
 
However, in most scenarios, the underlying associations between lung capacity measurements and 
risk of type 2 diabetes were assumed to be linear, eg Ford et al (2004) assessed the risk of incident 
type 2 diabetes by each 10ml decrease and 10% decrease of FEV1 and FVC
29
; Engstrom et al (2003) 
evaluated the decile decrease of FVC in prediction of the incident type 2 diabetes
28
. Few studies have 
set out to investigate the possible dose-response relationship between lung capacity measurements and 
risk of type 2 diabetes or MS. 
 
To our knowledge, this is the first study that has explored the dose-response relationship between lung 
capacity measurements and both type 2 diabetes and MS using two independent representative 
samples from two different countries.  Our results extend previous findings, suggesting that a non-
linear relationship exists between lung capacity measurements, FEV1 in particular, and glucose 
metabolism disorders, both type 2 diabetes and metabolism: The risk of type 2 diabetes and MS 
decreased over the 1.76 to 2.70L range of FEV1 but neither increased nor decreased below 1.76L or 
above 2.70L.  This was remarkably consistent in these two independent samples from two different 
countries. 
 
We wonder if this new information suggests that patients with obstructive lung disease below the 
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FEV1 threshold should be screened for diabetes and MS. This might reduce the potential to aggravate, 
unknowingly, undiagnosed dysglycaemia when commencing insulin antagonists such as steroids.   
Under the linear assumption of a dose-response relationship, there are no thresholds of lung capacity 
measurements, and therefore, it was previously difficult to propose a point for heightened awareness 
of the risk of significant hyperglycaemia. In the ARIC study, it was found that risk of incident 
diabetes was similar between women with average 2.6L of FEV1 and women with 2.9L of FEV1
4
. 
However in our refined explorations of the dose-response relationship and thresholds, a relatively 
precise threshold has now been generated.   
 
In our study, the threshold of 2.70L of FEV1 independent of age, gender, smoking, previous lung 
diseases, and adiposity, was identified both for type 2 diabetes and MS in both Chinese and Australian 
populations. An increased risk of type 2 diabetes and MS was more likely to be found among those 
with FEV1 below the threshold. Further studies should investigate whether the use of this threshold is 
cost-effective in both Western and Eastern populations. 
 
Our results are generally consistent with previous studies on graded lung capacity in MS and type 2 
diabetes, but this is the first time that a similar risk threshold has been reported. A similar 
FEV1threshold for type 2 diabetes and MS suggests that the pathological process (assumed to be 
inflammation, but potentially glycation 
29 
commences early.  This is supported by the relationship 
between fasting glycaemia and lung function in the general populations in both populations. 
 
Comparisons of independent survey data between countries allow opportunities to study the 
similarities and differences in the association between lung capacity and dysglycaemia. Both cross-
sectional survey datasets will incorporate variation by ethnicity, methodology and medical systems, 
potentially leading to variation in the prevalence of disease and clinical measurements.   For this 
reason, we have not merged these datasets for analysis 
 
There may also be underlying differences in the distribution of lung capacity and metabolic markers 
between countries and in the delivery and effectiveness of healthcare, contributing to observed 
difference in associations between lung capacity and metabolic disorders. However, it has been 
feasible to compare associations between nations by using a rigorous approach to data analysis.  
 
The approach we have used included a comparison of participant characteristics, levels of metabolic 
markers and the association between lung capacity measurements and metabolic markers.  This 
suggests that the two datasets in the two countries were comparable and this is supported by the 
consistency in the association between lung capacity measurements and metabolic disorders between 
the two populations.  
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The differences we observed were expected and may be partially explained by the smaller Australian 
sample size and ethnic differences. The latter could reflect different genetic backgrounds and 
anthropometry.  
 
The principal limitation of the present study is the use of cross-sectional data in both China and 
Australia, whereby spirometry variables and disease status were assessed at the same time. If disease 
progression changed lung function, it is difficult to deduce causation from the association between 
pulmonary function and metabolic disease.  Analysis of longitudinal study data would be the next step 
in examining these relationships further. Another limitation of this joint study is the data were not 
collected within the same survey: the data do appear comparable though. The temporary difference in 
data collection from the two nations might also have some impact on the research population. 
 
CONCLUSION 
In summary, our results suggest a non-linear relationship between FEV1 and risk of MS and type 2 
diabetes exists in both Chinese and Australian populations. The threshold of FEV1 for the lowest risk 
of type 2 diabetes and MS was above 2.70L (95%CI: 2.68 to 2.72L and 2.65 to 2.76L in Chinese and 
Australian population respectively). FEV1 below 2.70L was associated with a high risk of MS and 
type 2 diabetes. 
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Legends 
Figure 1. Forced expiratory volume in 1s and of forced vital capacity distribution by 
disease status.  
 
The figure shows the 25th, 50th (Median) and 75th percentile of the distribution of forced 
expiratory volume in 1s and of forced vital capacity (vertical lines on each box).  
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‘Whiskers’ on each box indicate values at 1.5 times the median (interquartile range) from the 
median and dots indicate the more extreme values, including the maximum and minimum of 
the distribution.   
MS, metabolic syndrome; DM, diabetes mellitus. 
(a) Distribution of FEV1 by disease status in Nanjing survey; 
(b) Distribution of FVC by disease status in Nanjing survey; 
(c) Distribution of FEV1 by disease status in Crossroads study; 
(d) Distribution of FVC by disease status in Crossroads study; 
 
Figure 2. Dose-response relationship between lung capacity measures (FEV1 and 
FVC) and odds ratios for type 2 diabetes both in Nanjing survey and Crossroads 
study 
 
All odds ratios were adjusted for age, gender, body mass index, smoking status, history of 
COPD or asthma, systolic blood pressure, diastolic blood pressure, total cholesterol, 
triglycerides, low-density lipoprotein cholesterol, and high density lipoprotein cholesterol.  
The solid line indicates the odds ratio and the dashed lines represent the 95% CI. 
 
(a) Dose-response relationship between FEV1 and odds ratios for type 2 diabetes in Nanjing survey; 
(b) Dose-response relationship between FEV1 and odds ratios for type 2 diabetes in Crossroads study; 
(c) Dose-response relationship between FVC and odds ratios for type 2 diabetes in Nanjing survey; 
(d) Dose-response relationship between FVC and odds ratios for type 2 diabetes in Crossroads study. 
 
Figure 3. Dose-response relationship between lung capacity measures (FEV1 and 
FVC) and odds ratios for metabolic syndrome both in Nanjing survey and Crossroads 
study 
 
All odds ratios were adjusted for age, gender, body mass index, smoking status, history of 
COPD or asthma, systolic blood pressure, diastolic blood pressure, total cholesterol, 
triglycerides, low-density lipoprotein cholesterol, and high density lipoprotein cholesterol.  
The solid line indicates the odds ratio and the dashed lines represent the 95% CI. 
 
a) Dose-response relationship between FEV1 and odds ratios for metabolic syndrome in Nanjing 
survey; 
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b) Dose-response relationship between FEV1 and odds ratios for metabolic syndrome in 
Crossroads study; 
c) Dose-response relationship between FVC and odds ratios for metabolic syndrome in Nanjing 
survey; 
d) Dose-response relationship between FVC and odds ratios for metabolic syndrome in 
Crossroads study. 
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Table 1. Characteristics of participants in all and by metabolic diseases status 
 All 
No metabolic 
syndrome/Type 2 
diabetes 
Metabolic 
syndrome 
Type 2 diabetes P 
 Nanjing Survey 
Participants, n 5824 3951 1401 472  
Age, years 52.0 (43.0 to 59.0) 51.0 (42.0 to 58.0) 54.0 (47.0 to 60.0) 56.0 (50.0 to 62.0) 0.0001 
Women, % 56.3% 53.2% 17.4% 24.2% <0.0001 
Current smoking, % 28.0% 33.7% 12.7% 24.4% <0.0001 
Asthma/COPD, % 1.1% 1.2% 1.0% 1.1% 0.836 
BMI, kg/m2 23.6 (21.4 to 26.1) 22.6 (20.7 to 24.5) 26.9 (24.9 to 28.9) 25.3 (22.9 to 27.6) 0.0001 
Waist circumference in men, cm 82 (75 to 89) 80.0 (74.0 to 86.1) 97.6 (95.5 to 100.6) 88.0 (81.0 to 92.9) 0.0001 
Waist circumference in women, cm 79.0 (72.0 to 86.0) 73.5 (69.1 to 77.4) 86.0 (83.0 to 91.0) 84.0 (78.1 to 90.7) 0.0001 
Systolic blood pressure, mmHg 128.0 (116.3 to 142.5) 124.0 (114.0 to 137.0) 137.0 (124.0 to 
151.0) 
137.0 (125.9 to 
157.0) 
0.0001 
Diastolic blood pressure, mmHg 80.5 (73.5 to 88.5) 78.5 (72.0 to 86.0) 85.5 (78.0 to 93.5) 85.0 (77.5 to 92.0) 0.0001 
Fasting glucose, mmol/L 5.4 (4.9 to 5.9) 5.3 (4.9 to 5.7) 5.4 (5.0 to 5.9) 7.7 (7.1 to 9.8) 0.0001 
Triglyceride, mmol/L 1.2 (0.8 to 1.7) 1.0 (0.7 to 1.5) 1.5 (1.1 to 2.2) 1.5 (1.0 to 2.5) 0.0001 
Total cholesterol, mmol/L 4.4 (3.9 to 4.9) 4.3 (3.8 to 4.8) 4.6 (4.1 to 5.1) 4.7 (4.1 to 5.4) 0.0001 
High density lipoprotein cholesterol, 
mmHg  
1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.6) 0.0001 
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Low density lipoprotein cholesterol, mmHg 2.4 (2.0 to 2.9) 2.4 (2.0 to 2.8) 2.5 (2.1 to 2.9) 2.5 (2.0 to 3.0) 0.0021 
 Crossroads study 
Participants, n 1454 890 420 137  
Age, years 52.0 (40.0 to 65.0) 48.0 (37.0 to 60.0) 55.0 (45.0 to 67.0) 64.0 (52.0 to 74.0) 0.0001 
Women, % 56.0% 59.7% 50.2% 49.6% 0.0020 
Current smoking, 18.9% 19.8% 18.8% 13.5% 0.2330 
Asthma/COPD, % 14.3% 14.2% 13.6% 16.5% 0.694 
BMI, kg/m2 27.0 (24.3 to 30.7) 26.0 (23.0 to 29.0) 30.0 (27.0 to 33.0) 30.0 (27.0 to 34.0) 0.0001 
Waist circumference in men, cm 100.0 (93.0 to 108.0) 95.0 (89.5 to 102.8) 105.6 (99.7 to 112.5) 106.3 (102.3 to 
114.4) 
0.0001 
Waist circumference in women, cm 88.0 (79.0 to 99.0) 83.4 (75.3 to 91.9) 97.5 (89.6 to 106.0) 101.5 (87.8 to 
110.5) 
0.0001 
Systolic blood pressure, mmHg 130.0 |(114.0 to145.0) 122.0 (111.0 to 137.0) 139.0 (127.0 to 
151.0) 
143.0 (127.0 to 
159.0) 
0.0001 
Diastolic blood pressure, mmHg 72.0 (65.0 to 79.0) 70.0 (64.0 to 77.0) 75.0 (69.0 to 82.0) 76.0 (68.0 to 83.0) 0.0001 
Fasting glucose, mmol/L 5.1 (4.8 to 5.5) 4.9 (4.7 to 5.2) 5.4 (5.1 to 5.8) 7.3 (6.2 to 8.8) 0.0001 
Triglyceride, mmol/L 1.2 (0.9 to 1.7) 1.0 (0.8 to 1.3) 1.9 (1.4 to 2.4) 1.7 (1.2 to 2.3) 0.0001 
Total cholesterol, mmol/L 5.2 (4.6 to 5.9) 5.2 (4.6 to 5.8) 5.4 (4.8 to 6.1) 4.7 (4.3 to 5.5) 0.0001 
High density lipoprotein cholesterol, 
mmol/L 
1.4 (1.1 to 1.6) 1.5 (1.3 to 1.8) 1.2 (1.0 to 1.4) 1.3 (1.0 to 1.5) 0.0001 
Low density lipoprotein cholesterol, 
mmol/L 
3.1 (2.6 to 3.7) 3.2 (2.6 to 3.7) 3.3 (2.7 to 3.9) 2.7 (2.3 to 3.3) 0.0001 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2. Association between various markers of glycemic status and FEV1 both in Nanjing Survey and 
Crossroad study 
Metabolic markers  
All 
No metabolic 
syndrome/Type 2 diabetes 
Metabolic syndrome Type 2 diabetes 
Model 1‡ Model 2† Model 1‡ Model 2† Model 1‡ Model 2† Model 1‡ Model 2† 
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
 Nanjing Survey 
Fasting glucose, mmol/L -0.08 (-0.14 to -
0.007) 
-0.08 (-0.15 to 
-0.01) 
0.02 (-0.02 to 
0.06) 
0.02 (-0.02 to 
0.06) 
-0.04 (-0.11 to 
0.03) 
-0.04 (-0.11 to 
0.03) 
0.07 (-0.47 to 
0.62) 
0.06 (-0.50 to 
0.61) 
Triglyceride, mmol/L 0.02 (-0.05 to 0.08) 
0.01 (-0.06 to 
0.08) 
0.02 (-0.04 to 
0.09) 
0.02 (-0.05 to 
0.08) 
-0.09 (-0.24 to 
0.06) 
-0.09 (-0.24 to 
0.06) 
0.48 (0.01 to 
0.94) 
0.47 (-0.01 to 
0.95) 
Total cholesterol, 
mmol/L 
0.01 (-0.03 to 0.06) 
0.02 (-0.02 to 
0.07) 
0.04 (-0.01 to 
0.09) 
0.06 (0.008 to 
0.11) 
-0.11 (-0.21 to -
0.01) 
-0.10 (-0.21 to -
0.002) 
0.13 (-1.00 to 
0.40) 
0.14 (-0.09 to 
0.37) 
High density lipoprotein 
cholesterol, mmol/L 
-0.001 (-0.17 to 
0.15) 
0.004 (-0.01 to 
0.02) 
0.006 (-0.013 to 
0.02) 
0.01 (-0.01 to 
0.03) 
-0.02 (-0.05 to 
0.013) 
-0.01 (-0.05 to 
0.02) 
-0.0007 (-0.067 
to 0.065) 
0.005 (-0.062 to 
0.073) 
Low densi y lipoprotein 
cholesterol, mmol/L 
0.004 (-0.03 to 
0.04) 
0.02 (-0.02 to 
0.005) 
0.03 (-0.01 to 
0.07) 
0.04 (-0.002 to 
0.08) 
-0.11 (-0.19 to -
0.018) 
-0.11 (-0.20 to -
0.02) 
0.019 (-0.16 to 
0.20) 
0.03 (-0.15 to 
0.21) 
 Crossroads study 
Fasting glucose, mmol/L -0.12 (-0.19 to -
0.05) 
-0.12 (-0.23 to 
-0.002) 
0.02 (-0.01 to 
0.05) 
0.02 (-0.04 to 
0.07) 
-0.03 (-0.09 to 
0.03) 
-0.03 (-0.12 to 
0.07) 
0.05 (-0.54 to 
0.64) 
0.04 (-0.90 to 
0.98) 
Triglyceride, mmol/L 0.05 (-0.02 to 0.12) 
0.04 (-0.04 to 
0.12) 
0.04 (0.0008 to 
0.08) 
0.04 (-0.01 to 
0.09) 
-0.14 (-0.31 to 
0.032) 
-0.13 (-0.40 to 
0.15) 
0.03 (-0.22 to 
0.28) 
0.04 (-0.35 to 
0.43) 
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Total cholesterol, 
mmol/L 
0.02 (-0.040 to 
0.08) 
0.03 (-0.06 to 
0.13) 
0.03 (-0.04 to 
0.10) 
0.06 (-0.05 to 
0.18) 
-0.04 (-0.16 to 
0.08) 
-0.02 (-0.22 to 
0.17) 
0.14 (-0.08 to 
0.36) 
0.16 (-0.19 to 
0.50) 
High density lipoprotein 
cholesterol, mmol/L 
0.02 (-0.002 to 
0.04) 
0.03 (-0.0001 
to 0.07) 
0.01 (-0.02 to 
0.04) 
0.04 (-0.006 to 
0.08) 
-0.03 (-0.06 to 
0.0006) 
-0.02 (-0.94 to 
0.90) 
0.001 (-0.08 to 
0.08) 
-0.008 (-0.13 to 
0.11) 
Low density lipoprotein 
cholesterol, mmol/L 
0.02 (-0.03 to 0.07) 
0.04 (-0.04 to 
0.13) 
0.02 (-0.04 to 
0.08) 
0.05 (-0.05 to 
0.15) 
-0.09 (-0.19 to 
0.01) 
-0.08 (-0.43 to 
0.26) 
0.01 (-0.20 to 
0.22) 
0.03 (-0.28 to 
0.35) 
‡ Results were adjusted for age, sex, and body mass index. 
†Results were adjusted for age, sex, body mass index, smoking status, and history of COPD or asthma. 
CI, confidence interval. 
 
 
Table 3. Association between various markers of glycemic status and FVC both in Nanjing Survey and Crossroad 
study 
Metabolic markers 
All 
No metabolic 
syndrome/Type 2 diabetes 
Metabolic syndrome Type 2 diabetes 
Model 1‡ Model 2† Model 1‡ Model 2† Model 1‡ Model 2† Model 1‡ Model 2† 
β (95% CI) β (95% CI)  β (95% CI)  β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
 Nanjing Survey 
Fasting glucose, mmol/L -0.15 (-0.21 to -
0.09) 
-0.16 (-0.22 to 
-0.10) 
-0.05 (-0.08 to -
0.02) 
-0.05 (-0.08 to -
0.02) 
-0.07 (-0.13 to -
0.02) 
-0.08 (-0.14 to -
0.02) 
-0.31 (-0.73 to 
0.12) 
-0.32 (-0.75 to 
0.11) 
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Triglyceride, mmol/L 0.04 (-0.02 to 0.09) 
0.03 (-0.03 to 
0.09) 
0.07 (0.01 to 
0.12) 
0.06 (0.01 to 
0.12) 
-0.003 (-0.13 to 
0.12) 
-0.005 (-0.13 to 
0.12) 
0.12 (-0.24 to 
0.48) 
0.11 (-0.27 to 
0.48) 
Total cholesterol, 
mmol/L 
-0.05 (-0.08 to -
0.01) 
-0.04 (-0.08 to 
-0.003) 
-0.02 (-0.06 to 
0.02) 
-0.01 (-0.05 to 
0.03) 
-0.10 (-0.19 to -
0.02) 
-0.11 (-0.19 to -
0.02) 
-0.05 (-0.23 to 
0.12) 
-0.05 (-0.23 to 
0.13) 
High density lipoprotein 
cholesterol, mmol/L 
-0.02 (-0.03 to -
0.01) 
-0.02 (-0.03 to 
-0.002) 
-0.02 (-0.04 to -
0.01) 
-0.02 (-0.04 to 
0.006) 
-0.005 (-0.03 to 
0.02) 
0.0008 (-0.03 to 
0.03) 
0.009 (-0.04 to 
0.06) 
0.02 (-0.04 to 
0.07) 
Low density lipoprotein 
cholesterol, mmol/L 
-0.06 (-0.09 to -
0.03) 
-0.05 (-0.08 to 
-0.02) 
-0.04 (-0.07 to -
0.002) 
-0.03 (-0.06 to 
0.005) 
-0.14 (-0.21 to -
0.02) 
-0.15 (-0.23 to -
0.07) 
-0.09 (-0.22 to 
0.05) 
-0.08 (-0.22 to 
0.06) 
 Crossroads study 
Fasting glucose, mmol/L -0.12 (-0.13 to -
0.11) 
-0.11 (-0.12 to 
-0.10) 
-0.08 (-0.12 to -
0.05) 
-0.07 (-0.12 to -
0.02) 
-0.09 (-0.15 to -
0.04) 
-0.11 (-0.17 to -
0.04) 
-0.47 (-1.02 to 
0.07) 
-0.53 (-1.29 to 
0.23) 
Triglyceride, mmol/L 0.05 (0.04 to 0.06) 
0.03 (0.02 to 
0.04) 
0.08 (0.07 to 
0.09) 
0.09 (0.14 to 
0.04) 
0.004 (-0.17 to 
0.17) 
0.003 (-0.18 to 
0.18) 
0.10 (-0.13 to 
0.33) 
0.12 (-0.33 to 
0.57) 
Total cholesterol, 
mmol/L 
-0.02 (-0.03 to -
0.01) 
-0.02 (-0.02 to 
-0.02) 
-0.05 (-0.06 to -
0.04) 
-0.04 (-0.06 to -
0.02) 
-0.10 (-0.22 to 
0.03) 
-0.10 (-0.27 to 
0.06) 
-0.12 (-0.33 to 
0.09) 
-0.21 (-0.52 to 
0.10) 
High density lipoprotein 
cholesterol, mmol/L 
-0.01 (-0.01 to -
0.01) 
-0.01 (-0.01 to 
-0.01) 
-0.007 (-0.009 to 
-0.005) 
-0.006 (-0.011 to 
-0.001) 
-0.01 (-0.04 to 
0.02) 
-0.01 (-0.08 to 
0.06) 
-0.05 (-0.13 to 
0.02) 
-0.06 (-0.15 to 
0.04) 
Low density lipoprotein 
cholesterol, mmol/L 
-0.02 (-0.03 to -
0.01) 
-0.02 (-0.02 to 
-0.02) 
-0.03 (-0.04 to -
0.02) 
-0.05 (-0.06 to -
0.04) 
-0.03 (-0.13 to 
0.07) 
-0.04 (-0.16 to 
0.09) 
-0.01 (-0.20 to 
0.18) 
-0.01 (-0.23 to 
0.21) 
‡ Results were adjusted for age, sex, and body mass index. 
†Results were adjusted for age, sex, body mass index, smoking status, and history of COPD or asthma. 
CI, confidence interval. 
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